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Objectives. In a double-blind, randomized, crossover trial we
sought to evaluate the effect of dual-chamber pacing in patients
with severe symptoms of hypertrophic obstructive cardiomyopa-
thy.
Background. Recently, several cohort trials showed that im-
plantation of a dual-chamber pacemaker in patients with severely
symptomatic hypertrophic obstructive cardiomyopathy can relieve
symptoms and decrease the severity of the left ventricular outflow
tract gradient. However, the outcome of dual-chamber pacing has
not been compared with that of standard therapy in a randomized,
double-blind trial.
Methods. Twenty-one patients with severely symptomatic hy-
pertrophic obstructive cardiomyopathy were entered into this trial
after baseline studies consisting of Minnesota quality-of-life as-
sessment, two-dimensional and Doppler echocardiography and
cardiopulmonary exercise tests. Nineteen patients completed the
protocol and underwent double-blind randomization to either
DDD pacing for 3 months followed by backup AAI pacing for 3
months, or the same study arms in reverse order.
Results. Left ventricular outflow tract gradient decreased sig-
nificantly to 55 6 38 mm Hg after DDD pacing compared with the
baseline gradient of 76 6 61 mm Hg (p < 0.05) and the gradient
of 83 6 59 mm Hg after AAI pacing (p < 0.05). Quality-of-life
score and exercise duration were significantly improved from the
baseline state after the DDD arm but were not significantly
different between the DDD arm and the backup AAI arm. Peak
oxygen consumption did not significantly differ among the three
periods. Overall, 63% of patients had symptomatic improvement
during the DDD arm, but 42% also had symptomatic improvement
during the AAI backup arm. In addition, 31% had no change and
5% had deterioration of symptoms during the DDD pacing arm.
Conclusions. Dual-chamber pacing may relieve symptoms and
decrease gradient in patients with hypertrophic obstructive car-
diomyopathy. In some patients, however, symptoms do not change
or even become worse with dual-chamber pacing. Subjective
symptomatic improvement can also occur from implantation of
the pacemaker without its hemodynamic benefit, suggesting the
role of a placebo effect. Long-term follow-up of a large number of
patients in randomized trials is necessary before dual-chamber
pacing can be recommended for all patients with severely symp-
tomatic hypertrophic obstructive cardiomyopathy.
(J Am Coll Cardiol 1997;29:435–41)
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Dual-chamber pacing has recently been proposed as an alter-
native to surgical myectomy for patients with severely symp-
tomatic hypertrophic obstructive cardiomyopathy unrespon-
sive to medical therapy (1–3). Several institutions have shown
that implantation of a dual-chamber pacemaker can reduce the
severity of left ventricular outflow tract gradient and relieve
symptoms in both short- and intermediate-term follow-up
periods (1–3). The mechanism for improvement is unclear but
may be related to both a short-term effect of gradient reduc-
tion by dyssynchronous contraction of the septum caused by
pacing the right ventricular apex and a more long-term effect
of ventricular remodeling (1). On the basis of these studies, it
has been proposed that dual-chamber pacing be performed in
all patients unresponsive to medical therapy before surgical
myectomy is considered (2).
All previous studies have consisted of cohorts in which
pacemakers were implanted and the patients were followed up
serially after the implantation. Two end points of the previous
studies were the labile left ventricular outflow gradient and
subjective symptomatic improvement, both of which can be
affected by factors other than direct hemodynamic improve-
ment. The purpose of this double-blind, randomized, crossover
trial was to evaluate objectively the effect of dual-chamber
pacing in patients with severely symptomatic hypertrophic
obstructive cardiomyopathy in whom medical therapy had
failed.
Methods
Patient entry criteria. The study group consisted of pa-
tients with hypertrophic obstructive cardiomyopathy who came
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to our institution between November 1993 and January 1995
with severe symptoms unresponsive to medical therapy. All
patients had the diagnosis of hypertrophic cardiomyopathy
established by conventional two-dimensional echocardio-
graphic criteria (2,4,5). For inclusion in this study, we required
a rest left ventricular outflow tract gradient .30 mm Hg at the
time of cardiac catheterization. For patients with a rest gradi-
ent ,50 mm Hg, a provoked gradient .50 mm Hg was
required for entry into the study. All patients had to be in
normal sinus rhythm at the time of entry into the study and
active enough to perform symptom-limited treadmill exertion
tests. Patients who were excluded included those with signifi-
cant concomitant valvular heart disease of aortic stenosis,
aortic regurgitation or mitral stenosis; those with mitral regur-
gitation thought to be caused by a primary valvular abnormal-
ity; and those with significant coronary artery disease (diame-
ter of stenosis .70% by visual estimation of a major epicardial
artery). The study was approved by the institutional review
board of the Mayo Clinic, and written informed consent was
obtained from all participants.
Initial evaluation. All patients were initially interviewed
and examined by one of two cardiologists (R.A.N., A.J.T.).
Symptoms were subjectively assessed by the New York Heart
Association functional classification. A Minnesota quality-of-
life form was used for a more objective measurement of the
patients’ functional capacity.
After the initial examination, comprehensive two-
dimensional and Doppler echocardiographic assessments were
performed. The peak instantaneous left ventricular outflow
tract gradient was measured by continuous wave Doppler
echocardiography (6–8). Mitral inflow velocity was measured
by the method previously described (9–12). The degree of
mitral regurgitation was assessed by color flow imaging.
A symptom-limited maximal treadmill exertion test was
done with a standard Mayo protocol and simultaneous analysis
of respiratory gases. Starting at 2.5 metabolic equivalents
(METs) for the first 2 min, the work load was increased by
2 METs every 2 min thereafter. Expired gas analysis was
performed using a Medical Graphics CPX cart. Maximal
oxygen consumption was defined as the highest 16-breath
average obtained during exercise.
Short-term hemodynamic catheterization was performed to
determine the immediate response of the left ventricular
outflow tract gradient to dual-chamber pacing using high
fidelity manometer-tipped catheter pressures and a transseptal
approach to avoid catheter entrapment (13). The details of this
study have been previously described (14). Simultaneous mitral
inflow velocity curves were measured by pulsed wave Doppler
echocardiography. Left atrial pressure, left ventricular pres-
sure, aortic pressure, pulmonary artery pressure and cardiac
output were measured in normal sinus rhythm and during
atrial synchronous pacing at varying atrioventricular intervals
(14,15). The optimal atrioventricular interval was documented
as that producing the lowest left ventricular outflow tract
gradient without a significant decrease in aortic pressure or
increase in left atrial pressure (2,14). In all patients, complete
right ventricular pre-excitation, as assessed by the QRS mor-
phology, was required to achieve the optimal hemodynamic
benefit.
Study design. On completion of the baseline tests, a per-
manent dual-chamber pacemaker was implanted. After 1 day,
to assure proper functioning of the pacemaker, the patients
were randomized in a double-blind, crossover fashion. In one
arm, the pacemaker was set at a backup AAI at a rate of 30
beats/min so that it would not be activated. In the other arm,
the pacemaker was set at a DDD mode, and the optimal
atrioventricular delay defined by the catheterization procedure
was used. Electrocardiographic monitoring at rest and during
light exercise was performed during DDD pacing to assure that
complete ventricular pre-excitation was present. The mitral
flow velocity curves during DDD pacing at the optimal atrio-
ventricular delay were similar to those obtained during the
temporary catheterization study when atrial synchronous pac-
ing was performed at the same atrioventricular delay, indicat-
ing similar mechanical atrial-ventricular synchrony.
The patients were then asked to perform telephone trans-
missions at monthly intervals. These transmissions were re-
viewed to assure that the pacemaker was continuing to func-
tion normally. So that the additive effect of dual-chamber
pacing could be determined, all patients continued to take the
same medications they were taking at presentation. Patients
were told to call their physician if their symptoms became
worse.
The patients returned for follow-up examination at 2- to
3-month intervals. The examination was repeated by an ob-
server who had no knowledge of the pacemaker setting. A
repeat subjective assessment of percent functional capacity was
made. The patients were asked whether their symptoms were
less severe, worse or unchanged. Another Minnesota quality-
of-life form was filled out. The comprehensive two-
dimensional and Doppler echocardiographic examinations and
the cardiopulmonary treadmill test were repeated. After the
repeat tests, the patients had their pacemakers programmed to
the opposite arm of the study. After another 2 to 3 months, the
above evaluation protocol was repeated.
Statistics. Data were expressed as mean value 6 SD. For
comparison of the measured variables among baseline, DDD
mode and backup AAI mode, a repeated measures analysis of
variance was used if the data approximated a gaussian distri-
bution. If the data did not sufficiently approximate a gaussian
distribution, Friedman’s procedure was used (for the changes
in left ventricular outflow gradient). For variables in which
there was a difference among the three periods, a pairwise
comparison among the three time points was made with a
Student-Newman-Keuls test when repeated measures analysis
of variance was performed or with a Bonferroni adjustment
when Friedman’s procedure was performed to adjust for the
problem of multiple comparisons. To assess the possibility of a
carryover effect after DDD pacing, a procedure based on totals
of the treatment arms was used (16). The Pearson and
Spearman correlation coefficients were used to assess the
association of clinical and catheterization variables with symp-
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tomatic response. Statistical significance was set a priori at p ,
0.05.
Results
Patient group. Twenty-one patients were entered into the
study protocol. One patient had continued severe limiting
symptoms after implantation of the pacemaker, despite place-
ment in the DDD arm. He subsequently underwent surgical
myectomy and was excluded from the study. Another patient
did not return for follow-up. Nineteen patients completed both
arms of the study and formed the basis of this analysis.
Of the 19 patients, 10 were men and 9 women, with a mean
age of 58 years (range 35 to 74). Eight of the patients had a
family history of hypertrophic cardiomyopathy. Concurrent
medications included beta-adrenergic blocking agents in 16
and calcium channel blocking agents in 10. Eight patients were
taking a combination of beta-blockers and calcium channel
blockers. The dosage range of beta-blockers was equivalent to
100 to 480 mg of propranolol, and the dosage range of calcium
channel blockers was equivalent to 240 to 480 mg of verapamil.
The medication dosage was held constant throughout the
protocol. One patient had a myectomy but had recurrent
symptoms and documented outflow tract gradient. Two pa-
tients had concomitant aortic valve disease but only mild
stenosis (gradient ,20 mm Hg and normal output). All
patients were in normal sinus rhythm and had a PR interval of
168 6 25 ms (range 120 to 200).
Baseline measurements. All patients had symptoms that
significantly limited their normal daily activity. Of the 19
patients, 1 was in functional class IV, 16 were in class III and
2 were in class II. The major symptom was dyspnea, which was
present in all patients. Twelve patients had exertional angina
and four had exertional presyncope. None of the patients had
experienced a complete syncopal event, and none had an
out-of-hospital arrest. The mean Minnesota quality-of-life
score was 55.1 6 23.7.
The mean septal thickness on two-dimensional echocardi-
ography was 2.2 cm (range 1.6 to 3.3). Systolic anterior motion
of the mitral valve was seen in all patients. The mean left
ventricular outflow tract gradient by Doppler echocardiogra-
phy at the time of outpatient echocardiography was 76 6
61 mm Hg (range 12 to 250). The degree of mitral regurgita-
tion was mild in 10 patients, moderate in 6 and severe in 1.
The mean exercise duration in the baseline state was 5.7 6
2.7 min. Maximal oxygen consumption achieved at peak exer-
cise was 19.4 6 6.7 ml/kg body weight per min. The indication
for stopping the exercise test was fatigue or shortness of breath
in all patients. No symptomatic supraventricular or ventricular
arrhythmias occurred during the exercise test.
Acute cardiac catheterization. The average gradient at
catheterization was 87 6 54 mm Hg (range 30 to 220). Five
patients had a rest gradient between 30 and 50 mm Hg. All five
of these patients had an increase in gradient to .100 mm Hg
during isoproterenol infusion. The mean left atrial pressure
was 19 6 9 mm Hg (range 3 to 36), and the mean left
ventricular end-diastolic pressure was 276 8 mm Hg (range 14
to 44). The optimal atrioventricular delay during dual-chamber
pacing was found to be the longest atrioventricular interval
possible before native anterograde conduction: 60 ms in 15
patients, 100 ms in 2 and 120 ms in 2. The average decrease in
gradient with dual-chamber pacing was 33 6 29 mm Hg (range
0 to 105). Thirteen patients had and six did not have a decrease
in the left ventricular outflow tract gradient with temporary
dual-chamber pacing.
Follow-up data (Table 1). Eleven patients were random-
ized to the AAI backup mode as the initial arm and eight to the
DDD pacing mode. No significant difference in heart rate or
blood pressure occurred at any of the three periods. There was
no significant evidence of a carryover effect due to the order of
the pacing modes when the end points of percent functional
capacity, Minnesota quality-of-life score, left ventricular out-
flow gradient, exercise duration and maximal oxygen consump-
tion were compared.
Figure 1 illustrates the symptomatic improvement per-
Figure 1. Subjective symptomatic response after each of the two
pacing arms. Shown are the percentages of patients (pts) who experi-
enced improvement, no change or deterioration from the baseline
state.Open columns5 continuous DDD pacing; gray columns5AAI,
backup mode with the atrial rate set at 30 beats/min.
Table 1. Follow-Up Data
Baseline
Pacing Mode
DDD AAI
HR (beats/min) 62.7 6 5.8 65.9 6 10.8 68.1 6 11.9
SBP (mm Hg) 136 6 22 136 6 19 126 6 19
LVO gradient (mm Hg) 76.76 61 54.9 6 38*† 83.4 6 59
QOL score 55.1 6 23.7 41.6 6 25.9* 48.4 6 23.2
NYHA class 2.9 6 0.4 2.4 6 0.7 2.6 6 0.7
Exercise duration (min) 5.7 6 2.7 6.9 6 2.2* 6.3 6 2.3
V˙O2max (ml/kg per min) 19.4 6 6.7 20.0 6 6.5 19.8 6 6.1
*p , 0.05 compared with baseline. †p , 0.05 compared with AAI. Data are
presented as mean value 6 SD. AAI 5 atrial paced, atrial sensed, inhibited;
DDD 5 dual-chamber paced, dual-chamber sensed, triggered inhibited; HR 5
heart rate; LVO 5 left ventricular outflow; NYHA 5 New York Heart
Association; QOL 5 quality of life; SBP 5 systolic blood pressure; V˙O2 5
maximal oxygen consumption.
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ceived by each patient during the follow-up periods. Sixty-three
percent of patients in the DDD-paced mode and 42% in the
backup unpaced mode (AAI) had symptomatic improvement
over the baseline state. With DDD pacing, 31% of patients felt
that symptoms were unchanged and 6% felt that symptomatic
status had deteriorated. The final functional classifications at
baseline and in the two different pacing modes are shown in
Figure 2. There were no significant differences in the average
functional classification among the three periods.
The Minnesota quality-of-life score was significantly lower
during DDD pacing than in the baseline state (41.6 6 25.9 vs.
55.1 6 23.7; p , 0.05). A lower score means fewer symptoms
or limitation of activity. There was no significant difference in
the score during backup AAI pacing compared with the
baseline state. However, the score was not significantly differ-
ent when DDD pacing was compared with backup AAI pacing
(Fig. 3).
Left ventricular outflow tract gradient during the DDD
pacing mode was significantly reduced from the baseline
value—from 76 6 61 to 55 6 38 mm Hg (p , 0.05) (Fig. 4).
The gradient in the AAI backup mode (83 6 59 mm Hg) was
essentially unchanged from that in the baseline state (76 6
61 mm Hg), but there was a high variability between the two
periods. The mean difference between the gradient in the
baseline state and that in the backup AAI mode was 211 6
41 mm Hg (Fig. 4).
Exercise duration was significantly improved in the DDD
arm from that at baseline—from 5.7 6 2.7 to 6.9 6 2.2 min
Figure 2. Change in New York Heart Association
classification (I–IV) of patients (arabic numerals) from
baseline (BASE) to DDD pacing for 3 months (left) or
backup AAI pacing for 3 months (right).
Figure 3. Changes in the objective measurements of symptoms, exer-
cise testing and gradient at three periods. Top left,Minnesota quality-
of-life score. Top right, Left ventricular outflow (LVO) gradient.
Bottom left, Duration of exercise on treadmill testing. Bottom right,
Maximal oxygen consumption (V˙O2) achieved during exercise testing.
Solid bars 5 baseline; open bars 5 DDD pacing; striped bars 5 AAI
pacing. Mean6 SD bars are shown. *p, 0.05 compared with baseline.
**p , 0.05 compared with AAI pacing.
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(p , 0.05). There was no significant difference in the exercise
time between the AAI arm and the baseline state. However,
exercise duration in the DDD pacing arm was not significantly
different from that in the AAI backup mode. Maximal oxygen
consumption achieved in either the DDD mode or the AAI
mode was not significantly changed from the baseline value
(Fig. 3). During exercise in the DDD pacing arm, anterograde
native atrioventricular conduction developed in two patients at
the maximal heart rate. The remaining 17 patients had com-
plete ventricular pre-excitation throughout the exercise test.
Association with symptomatic improvement during DDD
pacing. The baseline clinical and catheterization variables
were examined to determine if any were associated with
clinical subjective improvement during DDD pacing. Younger
age was associated with a higher perceived functional capacity
during DDD pacing (r5 20.46, p5 0.045). The mean baseline
left ventricular outflow gradient was higher in the patients who
had symptomatic improvement than in those who did not
(107 6 52 vs. 51 6 36 mm Hg; p 5 0.02). There was no
significant association between symptomatic improvement and
gender, left atrial pressure or drop in gradient during tempo-
rary pacing.
Discussion
The demonstration that implantation of a dual-chamber
pacemaker relieves symptoms and reduces left ventricular
outflow tract gradient in patients with severe symptomatic
hypertrophic cardiomyopathy has been met with great enthu-
siasm (1–3). However, the experience to date with dual-
chamber pacing has been limited to cohort trials from single
institutions. Before widespread application of a therapeutic
modality can be recommended, the true effect of the therapy
must be documented prospectively in a comparison with
conventional therapy without the influence of possibly con-
founding factors (17).
Effect of dual-chamber pacing on symptoms. In the study
herein, the short-term effect of dual-chamber pacing was
evaluated in a blind, randomized manner. The reason for the
backup AAI mode was to account for any “placebo” effect that
may occur whenever a treatment is instituted (18–20). Al-
though 63% of the patients had symptomatic improvement in
the DDD pacing mode, it is interesting that 42% of the
patients also reported symptomatic improvement when the
pacemaker was effectively off. The administration of any
treatment has both physiologic and psychological effects on the
patient, and these are interrelated (18–20). These placebo
effects can be potent, and because they act synergistically with
active treatment effects to influence patient outcome, they may
erroneously lead to improper interpretations of the results
of a treatment. For example, the Minnesota quality-of-life
score was statistically better after DDD pacing than during
the baseline state. After the permanent pacemaker had been
placed, however, there was no statistically significant differ-
ence in the quality-of-life score between the DDD mode and
the AAI backup mode. It may be more appropriate to
evaluate the true results of a technique by comparing them
with those of a similar placebo rather than with the baseline
data (18).
More than 30% of patients had no symptomatic improve-
ment (and 5% had symptomatic deterioration) during this
short follow-up period. This percentage is higher than any
reported in other studies, in which more than 90% of patients
experienced symptomatic improvement (1,2). Several differ-
ences in study design may contribute to this difference. One is
that administration of all medications was continued in the
current study after implantation of the permanent pacemaker.
The reason for continuing the medication was to determine the
additive effect of pacemaker therapy over conventional medical
therapy rather than to evaluate the isolated effect of pacing the
right ventricle. In patients with a dynamic outflow tract gradi-
ent, any therapy to reduce the degree of obstruction may be
less effective if negative inotropic agents are present. It is also
possible that discontinuation alone of medications associated
with a high incidence of side effects may result in subjective
symptomatic improvement. The length of follow-up was short
in the current study, so that any long-term consequences, such
as remodeling effects on the left ventricle, were not taken into
consideration. Thus, the results of this study need to be
compared with those of the initial short-term follow-up studies
(2) and should not be extrapolated for comparison with results
of the recently published longer term follow-up studies (1,3).
Figure 4. Doppler-derived left ventricular outflow
tract gradients in 19 patients. Left, Baseline (BASE)
and continuous DDD pacing are compared. There is a
significant decrease in the gradient during DDD pac-
ing (p, 0.05). Right, Baseline and backup AAI pacing
are compared. There is no significant difference be-
tween the two periods.
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In the initial short-term follow-up of 1.5 to 3 months, symp-
tomatic improvement was present in 95% of patients after
pacemaker implantation (2).
Effect of dual-chamber pacing on exercise testing and
gradient. The objective measurements of exercise tolerance
were of interest. There was a statistically significant increase in
exercise duration during the DDD mode over that in the
baseline state. As with the quality-of-life score, however,
exercise duration in the DDD mode was no greater than that
in the backup AAI mode. This finding raises the possibility of
a “training” effect of repetitive treadmill tests, which must be
taken into consideration when the results of therapy on
exercise duration are evaluated. No statistically different
change in maximal oxygen consumption was achieved during
either DDD pacing or the backup AAI mode in comparison
with the baseline value.
The left ventricular outflow tract gradient definitely de-
creased in the DDD pacing arm compared with the results in
either the baseline or the AAI backup arm, supporting the
findings of previous studies. The gradient may continue to
decrease with time if a remodeling effect occurs (1). However,
the left ventricular outflow tract gradient is known to be highly
variable and dynamic and perhaps should not be used as a
single, solid end point of therapy in patients with hypertrophic
obstructive cardiomyopathy (4,13). This characteristic is re-
flected in the wide variation in the measured gradient from the
baseline state to the backup AAI mode, with differences
.100 mm Hg without intervention.
The residual gradient in most patients was still substantial
with dual-chamber pacing. In addition, factors other than just
the outflow tract gradient need to be evaluated to determine
the efficacy of pacing on the pathophysiologic mechanisms in
patients with hypertrophic obstructive cardiomyopathy. A
complex interplay of many other interrelated processes, includ-
ing diastolic dysfunction, mitral regurgitation and arrhythmias,
contributes to symptoms in these patients (4,13,21). The effect
of long-term dual-chamber pacing on these other processes in
patients with hypertrophic cardiomyopathy remains to be
elucidated.
Study limitations. The number of patients in the study was
small, and larger numbers may be required to show statistically
significant differences. As in any crossover trial, a carryover
effect may be present in patients randomized to the placebo
arm after the true intervention arm. Fananapazir et al. (1,2)
showed that the left ventricular outflow tract gradient
continues to decrease even after the pacemaker has tempo-
rarily been turned off, suggesting a remodeling process of
the left ventricle. This carryover effect cannot be ruled out
in this study as the reason for the mild trend toward
improvement in the entire group during the AAI backup
mode. However, 11 of the 19 patients were randomized to
the AAI mode first, and the results from these 11 patients
were no different from those in the remaining 8 patients who
were randomized to a DDD pacing mode during the initial
arm of the study.
Caution must be applied when examining the associations
of baseline characteristics with symptomatic improvement. The
number of patients was small, and type 1 statistical errors could
be present. The relations shown were poor and may not be
clinically useful unless these associations can also be shown in
multicenter studies of a larger number of patients.
The relatively short duration (2 to 3 months) in the DDD
mode may not have allowed sufficient time for significant
improvement in maximal oxygen consumption because of
increased physical activity secondary to improved symptomatic
status. The short duration of follow-up may not have allowed
for the full hemodynamic effect of DDD pacing to occur, as
there may be a remodeling process with time (1). Further
symptomatic and hemodynamic improvement has been shown
with continued pacing for over 2 years compared with the
initial results of pacing for 1.5 to 3 months (1).
Clinical implications. The results of this study should not
be interpreted as indicating that dual-chamber pacing is not
beneficial in patients with severely symptomatic hypertrophic
obstructive cardiomyopathy. A number of patients in this study
achieved both symptomatic and hemodynamic improvement
from dual-chamber pacing. A statistically significant improve-
ment in exercise duration, quality-of-life score and left ventric-
ular outflow tract gradient was achieved during dual-chamber
pacing compared with baseline values. Also, further improve-
ment in both symptoms and hemodynamic data may occur with
time, because a late remodeling effect of pacing the right
ventricle can result (1). The placebo effect alone is time-limited
and would not account for the long-term improvement shown
in previous studies.
For advocates of routine implantation of permanent pace-
makers in all patients with symptomatic hypertrophic cardio-
myopathy, however, this study should provide some reserva-
tion. A subset of patients will not have a beneficial response
to this therapy, and patients must be made aware of this
potential outcome. In addition, at selected institutions
surgical myectomy can now be performed at low risk with a
high rate of success in abolishing gradient and improving
symptoms (22–27). The excellent long-term outcome after
surgical myectomy has been documented (28). Thus, surgi-
cal intervention should still be considered a therapeutic
option in selected patients.
Many questions have not been answered by this small,
preliminary, single-center study (17). More patients need to be
studied in this manner to attempt to determine predictors of
whether improvement will occur with dual-chamber pacing.
Longer follow-up is also required to see the extent of further
improvement from the proposed remodeling process of long-
term dual-chamber pacing as well as any potential detrimental
effects. Several multicenter randomized trials that may answer
these questions are in progress. Until the results of these trials
become available, however, physicians should be aware of the
limitations of routine implantation of permanent pacemakers
and the role the placebo effect may play, as well as be cognizant
of other options available for patients with severely symptom-
atic hypertrophic obstructive cardiomyopathy.
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